The collaboration between Nigeria and a Chinese company in September 2025 to build West Africa’s first insulin manufacturing plant in Abuja marks a significant milestone under the “Health Silk Road” initiative. This agreement follows a series of partnerships between companies from both countries to establish facilities for producing antimalarial drugs and antiretroviral medications. Although these are bilateral commercial agreements between private-sector entities, they collectively form an integral part of China’s broader vision for advancing global health.
As China’s economic strength and technological capabilities continue to grow, it has emerged as a major player in the global health landscape. Beijing favors a model of bilateral cooperation that emphasizes national sovereignty and is grounded in principles of equal partnership and solidarity among nations. This approach spans multiple domains—from improving population health and accelerating digital transformation in healthcare to manufacturing off-patent medicines, thereby expanding affordable access to essential treatments.
Countries can leverage this dynamic by engaging in partnerships with China, benefiting from the speed and efficiency of its foreign development assistance model and the robustness of its thriving private sector. Such collaborations can particularly capitalize on China’s strong platforms in vaccine manufacturing and digital health innovation—provided they are accompanied by effective oversight and accountability mechanisms from multilateral institutions and relevant government bodies.
Health remains a central priority for China at local, national, and international levels alike. Long-term policy documents such as the “Healthy China 2030” plan and successive Five-Year Plans consistently reaffirm ambitious goals, including achieving universal health coverage, ensuring access to essential medicines, and implementing integrated strategies to address challenges such as population aging, the rising burden of non-communicable diseases, and future pandemic risks.
In recent years, China has transitioned from being a recipient to a provider of global health assistance. Its cooperation with Tanzania serves as a notable example. Drawing on its own successful experience in reducing malaria cases from approximately 30 million annually in the 1940s to fewer than 5,000 by 2013, China has supported Tanzania and other countries in designing similar malaria control strategies. According to data from the Chinese Center for Disease Control and Prevention, malaria incidence in targeted areas of Tanzania dropped by 80% between 2015 and 2018.
At the 2024 Forum on China–Africa Cooperation (FOCAC), China achieved tangible progress in bolstering Africa’s pharmaceutical manufacturing capacity—a success rooted in China’s own rapid expansion of its domestic pharmaceutical industry. This trend not only reflects China’s commitment to its role as a global health leader but also demonstrates its ability to apply its national experiences to help other countries achieve shared global health objectives.
China’s role in global health is expected to expand significantly in the coming years—and decades. As a global frontrunner in fields such as digital health, electronic medical records, and AI-driven diagnostics and treatment, China is likely to integrate these capabilities into the framework of the “Health Silk Road” in future partnerships with friendly nations.
As the world enters a new era of global health cooperation, the article concludes that the “Health Silk Road” has the potential to become an effective instrument for enhancing the resilience and inclusiveness of the global health system.